268 related articles for article (PubMed ID: 19755677)
1. Epigenetic therapies move into new territory, but how exactly do they work?
Tuma RS
J Natl Cancer Inst; 2009 Oct; 101(19):1300-1. PubMed ID: 19755677
[No Abstract] [Full Text] [Related]
2. Use of hypomethylating agents in myelodysplastic syndromes.
Atallah E; Garcia-Manero G
Clin Adv Hematol Oncol; 2007 Jul; 5(7):544-52. PubMed ID: 17679928
[TBL] [Abstract][Full Text] [Related]
3. Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?
Lowder JN; Taverna P; Issa JP
Epigenomics; 2015 Oct; 7(7):1083-8. PubMed ID: 26541345
[No Abstract] [Full Text] [Related]
4. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.
Estey EH
Leukemia; 2013 Sep; 27(9):1803-12. PubMed ID: 23757301
[TBL] [Abstract][Full Text] [Related]
5. [Epigenetic therapy in myelodysplastic syndromes (MDS). Treatment with DNA methyltransferase inhibitors].
Daskalakis M; Blagitko-Dorfs N; Hackanson B; Lübbert M
Pharm Unserer Zeit; 2010 May; 39(3):217-27. PubMed ID: 20425776
[No Abstract] [Full Text] [Related]
6. [Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk myelodysplastic syndrome].
Maeda Y
Rinsho Ketsueki; 2014 Oct; 55(10):1870-81. PubMed ID: 25297751
[No Abstract] [Full Text] [Related]
7. Current status of epigenetic treatment in myelodysplastic syndromes.
Kuendgen A; Lübbert M
Ann Hematol; 2008 Aug; 87(8):601-11. PubMed ID: 18392623
[TBL] [Abstract][Full Text] [Related]
8. [Epigenetic therapy in myelodysplastic syndromes].
Maki K; Mitani K
Rinsho Ketsueki; 2011 Jul; 52(7):438-46. PubMed ID: 21821974
[No Abstract] [Full Text] [Related]
9. Digging deep into "dirty" drugs - modulation of the methylation machinery.
Pleyer L; Greil R
Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
[TBL] [Abstract][Full Text] [Related]
10. Combining DNA methyltransferase and histone deacetylase inhibition to treat acute myeloid leukemia/myelodysplastic syndrome: achievements and challenges.
Lübbert M; Kuendgen A
Cancer; 2015 Feb; 121(4):498-501. PubMed ID: 25336205
[No Abstract] [Full Text] [Related]
11. Targeting DNA methylation.
Issa JP; Kantarjian HM
Clin Cancer Res; 2009 Jun; 15(12):3938-46. PubMed ID: 19509174
[TBL] [Abstract][Full Text] [Related]
12. Six (or more) drugs in search of a mechanism: DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes.
Gore SD
J Natl Compr Canc Netw; 2006 Jan; 4(1):83-90. PubMed ID: 16403407
[TBL] [Abstract][Full Text] [Related]
13. DNA Methyltransferase Inhibitors in Myeloid Cancer: Clonal Eradication or Clonal Differentiation?
Ørskov AD; Grønbæk K
Cancer J; 2017; 23(5):277-285. PubMed ID: 28926428
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic regulation in myelodysplastic syndromes: implications for therapy.
Vigna E; Recchia AG; Madeo A; Gentile M; Bossio S; Mazzone C; Lucia E; Morabito L; Gigliotti V; Stefano LD; Caruso N; Servillo P; Franzese S; Fimognari F; Bisconte MG; Gentile C; Morabito F
Expert Opin Investig Drugs; 2011 Apr; 20(4):465-93. PubMed ID: 21381982
[TBL] [Abstract][Full Text] [Related]
15. DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action.
Lübbert M
Curr Top Microbiol Immunol; 2000; 249():135-64. PubMed ID: 10802943
[No Abstract] [Full Text] [Related]
16. Multifaceted modes of action of azacytidine: a riddle wrapped up in an enigma.
Lamprianidou E; Zoulia E; Bernard E; Kordella C; Papoutselis M; Bezirgiannidou Z; Vrachiolias G; Papaemmanuil E; Kotsianidis I
Leuk Lymphoma; 2019 Dec; 60(13):3277-3281. PubMed ID: 31185765
[No Abstract] [Full Text] [Related]
17. Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors.
Cowan LA; Talwar S; Yang AS
Epigenomics; 2010 Feb; 2(1):71-86. PubMed ID: 22122748
[TBL] [Abstract][Full Text] [Related]
18. DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes.
Griffiths EA; Gore SD
Semin Hematol; 2008 Jan; 45(1):23-30. PubMed ID: 18179966
[TBL] [Abstract][Full Text] [Related]
19. Improving the outlook for myelodysplastic syndrome.
Brower V
J Natl Cancer Inst; 2012 Aug; 104(16):1204-6. PubMed ID: 22899627
[No Abstract] [Full Text] [Related]
20. Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma.
Venturelli S; Armeanu S; Pathil A; Hsieh CJ; Weiss TS; Vonthein R; Wehrmann M; Gregor M; Lauer UM; Bitzer M
Cancer; 2007 May; 109(10):2132-41. PubMed ID: 17407132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
